One In Three Japanese Physicians Have Doubts Over Chinese, Korean Study Data
This article was originally published in PharmAsia News
A new survey conducted by Tokyo-based Medpeer finds that 33% of physicians in Japan have reservations about clinical studies conducted in China and South Korea
You may also be interested in...
Potentially transformative treatments for severe asthma, COPD and osteoarthritis are among some of the below-the-radar projects the Swiss major is advancing, according to Vas Narasimhan.
Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.
In the second segment of a two-part article on transparency provisions for the new EU clinical trial portal, a senior Merck executive explains how the company will ensure that commercially sensitive information and personal data in its clinical trial applications are not made public.